INTENSITY THERAPEUTICS, INC. (INTS): Nasdaq/NYSE listing notice — Intensity Therapeutics receives Nasdaq minimum bid price deficiency notice

INTENSITY THERAPEUTICS, INC.

Nasdaq notified INTS on June 6, 2025 that bid price was below $1.00 for 30 consecutive business days.
Company has a 180-day grace period, until December 3, 2025, to regain compliance.
Compliance can be achieved if closing bid price is $1.00 or more for 10 consecutive business days.
If not compliant by deadline, INTS may seek a second grace period or consider a reverse stock split.
No immediate effect on listing or trading; stock continues on Nasdaq Capital Market under symbol INTS.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

INTENSITY THERAPEUTICS, INC. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

June 6, 2025, Intensity Therapeutics, Inc. (the “Company”) received a letter from The Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the preceding 30 consecutive business days the Company’s common stock did not maintain a minimum closing bid price of $1.00 per share as required by Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The notice has no immediate effect on the listing or trading of the Company’s common stock, and the common stock will continue to trade on The Nasdaq Capital Market under the symbol “INTS” at this time. In accordance with Nasdaq List

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

INTENSITY THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001567264-25-000056

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.